FibroBiologics Inc. Commo... (FBLG)
NASDAQ: FBLG
· Real-Time Price · USD
0.54
-0.06 (-10.36%)
At close: Sep 25, 2025, 3:59 PM
0.56
3.06%
After-hours: Sep 25, 2025, 04:59 PM EDT
-10.36% (1D)
| Bid | 0.53 |
| Market Cap | 22.61M |
| Revenue (ttm) | 554K |
| Net Income (ttm) | -13.22M |
| EPS (ttm) | -0.36 |
| PE Ratio (ttm) | -1.5 |
| Forward PE | -0.99 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.56 |
| Volume | 695,840 |
| Avg. Volume (20D) | 531,946 |
| Open | 0.59 |
| Previous Close | 0.60 |
| Day's Range | 0.53 - 0.59 |
| 52-Week Range | 0.51 - 3.89 |
| Beta | -0.71 |
| Ex-Dividend Date | n/a |
About FBLG
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FBLG
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FBLG stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+22.67%
FibroBiologics shares are trading higher. The comp...
Unlock content with
Pro Subscription
9 months ago
-0.87%
FibroBiologics shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a price target of $12.
2 months ago · https://www.marketscreener.com
Fibrobiologics Confirms Ability to Manufacture Cybrocell for Degenerative Disc Disease and Cartilage Repair Programs from Existing Cywc628 Master Cell BankFibroBiologics, Inc. announced an advancement in its cartilage repair program. FibroBiologics has confirmed, through both immunohistochemistry and transcriptomic analysis, that the CYWC628 spheroids u...